External broker reports(aggregated public sources), CMB International

CMB International

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

External broker reports(aggregated public sources)

Equity Bottom-Up

Shenzhen Mindray Bio-Medical Electronics / Equity Bottom-Up

Shenzhen Mindray Bio-Medical Electronics (300760 CH)

<ul><li>Mindray reported 9M24 revenue of RMB29.5bn, up by 8.0% YoY. Attributable net profit increased by 8.2% YoY to RMB10.6bn.</li><li>Revenue in 3Q24 grew by 1.4% YoY to RMB9.0bn while attributable net profit decreased by 9.3% YoY to RMB3.1bn.</li><li>The slowdown in revenue growth can primarily be attributed to lackluster procurement activities in domestic public hospitals and weakened demand for IVD testing, particularly in lower-tier hospitals. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Mindray reported 9M24 revenue of RMB29.5bn, up by 8.0% YoY. Attributable net profit increased by 8.2% YoY to RMB10.6bn.Revenue in 3Q24 grew by 1.4% YoY to RMB9.0bn while attributable net profit decreased by 9.3% YoY to RMB3.1bn.The slowdown in revenue growth can primarily be attributed to lackluster procurement activities in domestic public hospitals and weakened demand for IVD testing, particularly in lower-tier hospitals. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Mindray (300760 CH) - Expect Domestic Business to Rebound from 2025